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Abstract
Background: Very low birth weight (less than 1500 g) is associated with increased morbidity and costs of health
care in childhood. Emerging evidence suggests these infants face a range of health and social problems as young
adults. We studied all New Zealand very low birth weight infants born in 1986 (when 58 % were exposed to
antenatal corticosteroids) in infancy, with later follow-up at 7 to 8 years and 23 to 24 years. We now aim to assess
the cohort at 26–28 years compared with controls.
Methods/design: The case sample will comprise a minimum of 250 members of the 1986 New Zealand national
very low birth weight cohort (77 % of survivors). Outcomes will be compared with a control group of 100 young
adults born at term in 1986. Following written informed consent, participants will travel to Christchurch for 2 days
of assessments undertaken by experienced staff. Medical assessments include growth measures, vision, respiratory
function, blood pressure and echocardiogram, renal function, dental examination and blood tests. Cognitive and
neuropsychological functioning will be assessed with standard tests, and mental health and social functioning by
participant interview. A telephone interview will be conducted with a parent or significant other person nominated
by the respondent to gain a further perspective on the young person’s health and functioning. All those born at
less than 28 weeks’ gestation, plus a random subset of the cohort to a total of 150 cases and 50 controls, will be
offered cranial magnetic-resonance imaging. Statistical analysis will examine comparison with controls and long-term
trajectories for the very low birth weight cohort.
Discussion: The research will provide crucial New Zealand data on the young adult outcomes for very low birth
weight infants and address gaps in the international literature, particularly regarding cardiovascular, respiratory, visual
and neurocognitive outcomes. These data will inform future neonatal care, provide evidence-based guidelines for care
of preterm graduates transitioning to adult care, and help shape health education and social policies for this high risk
group.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12612000995875. Registered 1 October 2012
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Background
Infants born very low birth weight (VLBW: <1500 g) or
very preterm (VP: <32 weeks gestation) account for
around 2 % of live births but between 50–75 % of the
work load of neonatal intensive care units (NICUs) [1].
Whilst survival rates for these infants now exceed 90 %,
[2, 3] what is most important for individuals, their fam-
ilies and society is the quality of that survival in the lon-
ger term. Knowledge of longer-term outcomes is also
crucial to inform current neonatal care.
An extensive literature has documented increased
rates of health problems amongst surviving VLBW/VP
infants compared with full term infants in their early
years, including sudden infant death syndrome, feeding
problems, respiratory disorders, and increased hospital-
isation [4]. Adverse outcomes are also common through-
out childhood and include poor growth, neurosensory
impairments such as cerebral palsy (CP) in up to10 % or
more, and up to 50 % have behavioural problems, cogni-
tive delay, or educational underachievement [5–11].
Woodward [12] reported that 72 % of VP infants have
some white matter (WM) changes on cranial MRI scans
at term equivalent, and that moderate or severe changes
(in 21 %) were predictive of CP and neuro-cognitive
problems in early childhood. These abnormalities in-
clude reduced WM volume, ventriculomegaly, thinning
of the corpus callosum and delayed myelination. The
impacts of these neonatal neurological abnormalities on
adult brain structure and function are not known. How-
ever, findings from cross sectional studies in childhood
and adolescence, [13–15] and a recent cohort study, [16]
suggest that abnormalities persist and may be irreversible.
Data are also now emerging on a range of functional
and health related challenges faced by former VLBW/VP
infants as they reach young adulthood, [17, 18] although
the majority appear to do well overall [19–21]. Scandi-
navian data show that preterm birth and particularly
lower gestational age is associated with increased mor-
tality in young adulthood, [22, 23] with congenital ab-
normalities, respiratory, endocrine and cardiovascular
problems all increasing hazard ratios for risk of death
[23]. Studies of growth of VLBW/VP children show that
following early growth failure there is some catch-up
that may continue through adolescence, although young
adults remain shorter and often lighter than their peers
[24]. Specific health issues found to be more prevalent
include an increased risk of hypertension, [18, 25, 26]
impaired insulin sensitivity, [27] glucose tolerance, [28]
and renal function [29, 30] and abnormal respiratory
function [25, 31]. VLBW children have a greater risk of
asthma at school age than controls [32] and infants who
had chronic lung disease have poorer lung function in
late adolescence [25]. In addition, most reports to date
indicate that former VLBW/VP young adults do have
lower median IQ scores than their peers, even after ex-
cluding those with neurosensory impairments and con-
trolling for confounding factors. Relatively fewer
VLBW/VP survivors graduate from high school or
enter tertiary education [17, 18, 33]. And even when
free of major physical disability, VP young adults per-
formed less well on tasks involving mental flexibility
and response inhibition [34].
There are no New Zealand data in this crucial area
and important gaps exist in the international literature.
To address both these issues we will follow-up the 1986
New Zealand national cohort of VLBW infants, at age
26–28 years.
In 1986 we enrolled all 413 New Zealand VLBW in-
fants admitted to a neonatal intensive care unit (NICU)
as part of a prospective study of acute retinopathy of
prematurity. Of these, 338 infants (82 %) survived to dis-
charge home [35, 36]. Extensive perinatal data collection
showed that at birth 58 % had received antenatal steroids,
132 (32 %) were <1000 g, 126 (31 %) were <28 weeks ges-
tation, 103 (25 %) were small for gestational age, and 95
(23 %) were Maori. Survival for both those <1000 g and
<28 weeks was 64 % [2, 36].
This cohort was followed-up at 7 to 8 years and as-
sessments conducted to examine visual and develop-
mental outcomes. By this age a further 12 children had
died, 17 were traced to an overseas address, seven fam-
ilies declined follow-up and four were untraced. Hence
we assessed 298 children (96 % survivors resident in NZ,
91 % all survivors): 5 % had severe disability, 5 % moder-
ate disability and 15 % mild disability, which was princi-
pally an IQ between 1 to 2 SDs below the mean [9].
Compared with the Christchurch Health and Develop-
ment Study cohort studied at the same age, [37] the
VLBW cohort had higher rates of behavioural problems
(conduct disorders, attention problems, anxiety/with-
drawal), and poorer school achievement [10]. These dif-
ferences increased with decreasing birthweight amongst
the VLBW sample.
In 2009–10, when the members of the cohort were 23
to 24 years old, they were re-contacted as part of a feasi-
bility study in preparation for funding applications for
the current project. VLBW graduates were traced
through their addresses at 7 to 8 years, grandparents’ ad-
dresses, general practitioners, National Health Index
(NHI) codes (NHI – a unique person identifier used
within the New Zealand health system since 1993), via
the electoral rolls and, in a limited number of cases, by
local advertisements. Checks were made with Statistics
New Zealand to see if any individuals had died since last
follow-up. A comparison group (controls) of individuals
who were born full-term (FT) in New Zealand in 1986
and were not admitted for NICU care, was recruited ei-
ther through peer nomination by cohort members or via
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random sampling from electoral rolls, ensuring balance
with respect to the gender, ethnicity and regional distri-
bution of the sample.
A total of 276 (85 % of 324) survivors were retraced and
230 (71 %) enrolled in this pilot (Phase 1) study, which
comprised a face-to-face interview to collect information
about each participant’s social background, health, educa-
tion and social role outcomes, supplemented by informa-
tion from medical records [38]. Sixty-nine controls were
also recruited.
The present (Phase 2) study has two primary aims.
The first aim is to assess the health, mental status, func-
tional outcome and quality of life in young adulthood of a
NZ national VLBW cohort born in 1986 compared with a
group of full-term children born in the same year.
We hypothesise that compared to their same age full
term peers, adults born VLBW will, at age 26–28 years,
have:
1. Lower levels of school attainment and tertiary
educational participation, more limited occupational
choice and higher levels of welfare dependence
2. Higher levels of inattention, impulsivity and
emotional problems (i.e., symptoms of anxiety and
depression), but lower levels of alcohol and drug
use/abuse, antisocial behaviour and police contact.
3. Lower social participation and poorer social
functioning
4. Poorer performance on measures of cognitive ability,
information processing and executive functioning
5. Increased rates of cardiovascular, endocrine,
pulmonary, renal and visual abnormalities and
pathology
Specifically, regarding cardiovascular assessments,
we anticipate:
– Lower reactive hyperaemia consistent with
more endothelial dysfunction
– Echocardiograms that show more abnormalities
in LV size and function
– Elevation of BNP and other cardiac biomarkers
and related signalling peptides, that reflect the
degree of cardiovascular abnormality and will
predict future cardiovascular events
regarding endocrine assessments, we anticipate:
– Higher indices of insulin resistance and glucose
intolerance
regarding pulmonary function, we anticipate:
– Impaired pulmonary function, including
reduced lung volumes and diffusing capacity,
reduced exercise capacity, and higher rates of
respiratory morbidity.
regarding renal function, we anticipate:
– Higher microalbumin excretion and lower
creatinine clearance
regarding vision, we anticipate:
– Less favourable structural outcomes and
impaired functional ability
6. Poorer dental health and dental hygiene
7. Increased rates of both macro- and micro-structural
abnormalities on cranial MRI scans
The second aim is to assess whether childhood
health and developmental outcomes are predictive of
later young adult outcomes within the VLBW cohort.
We hypothesise that within the VLBW cohort:
8. Young adults who were characterised by significant
disability/cognitive impairment at 7 to 8 years will
fare less well on measures 1–4 than VLBW adults
without early impairment [39].
9. Young adults who had retinopathy of prematurity
(ROP) and visual impairments at 7 to 8 years will
have more adverse visual problems than those who
had no ROP.
10. Young adults who had neonatal chronic lung
disease (CLD) will have more adverse respiratory
function than those who no CLD
11. Increased duration of breastfeeding will be
associated with a small but measurable advantage in
cognitive outcomes
12. There will be increasing social and economic
disadvantage with decreasing birthweight and
increasing prematurity.
In our preliminary (Phase 1) study we re-established
the cohort and began to address hypotheses 1–3. This
Phase 2 study will extend the research to focus on
health issues and neurocognitive outcomes but also to
update the information collected as part of Phase 1.
Design and methods
Study population
The case sample will comprise a minimum of 250
members of the 1986 NZ National VLBW cohort
(77 % of survivors). In Phase 1 the proportion (%) of
the 230 survivors seen and other survivors not
assessed (94) who were <1000 g was 25.2 and 27.1;
were <28 weeks is 24.8 and 24.0; are male is 47.0
and 52.1; are Maori is 26.1 and 22.1; had moderate/
severe disability at 7 to 8 years is 10.3 and 6.7 – all
being not significantly different. Outcomes for the
VLBW cohort will be assessed against a comparison
sample of 100 same age term controls recruited via a
process of peer nomination and random sampling
from electoral rolls, ensuring balance with respect to
the gender, ethnicity and regional distribution of the
sample.
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Procedures
As part of Phase 1 all participants have been informed
about Phase 2 of the study and have consented to being
approached to participate in these assessments. The
study has also obtained comprehensive contact infor-
mation for each participant, plus a number of individ-
uals not studied in Phase I, and we do not anticipate
major difficulties in tracing and consenting participants
for Phase 2. Following consent, participants will be
brought to Christchurch for a 2 day multidisciplinary
evaluation (an average of three participants a week).
Provision will be made for a support person to travel
with the participant if this is required. All costs of
travel, accommodation and food will be met by the
study. For the small number of the cohort members
who are too compromised to travel to Christchurch due
to disability severity and/or care needs we will seek in-
formation by means of a questionnaire and, where pos-
sible, a visit from one of the research team (Additional
files 1, 2, 3, 4, 5, 6).
All research procedures will be conducted in exist-
ing facilities in the University of Otago, Christchurch
or Canterbury District Health Board (CDHB). Partic-
ipants will be scheduled to arrive the night before,
have fasting blood tests the next morning and a
series of assessments over 2 days. Study personnel
will meet each participant and assist their navigation
between laboratory sessions. To avoid problems of
fatigue, participants will have the opportunity to take
breaks as necessary and refreshments as required.
Transportation will also be provided when needed.
Medical investigations will be undertaken in the University
of Otago, Christchurch, Department of Medicine Nicholls
Clinical Research Centre and the CDHB Respiratory
Physiology Laboratory facilities.
Assessments will be conducted by appropriately
trained, medically qualified staff, who will be blinded
to the participant’s background (except where noted
otherwise), and will include:
▪ Standardised questionnaires on health, including
respiratory [40] and bowel problems.
▪ Growth-height (Harpenden stadiometer), weight,
BMI (Weight/Height2), waist-hip ratio, head
circumference.
▪ Total body fat estimated by bioelectrical impedance
analysis (BIA).
▪ Visual assessment. Glasses prescription-measured in
focimeter. Distance visual acuity using standardised
ETDRS chart (with glasses if worn). Contrast sensitivity
testing with Pelli-Robson charts (which reflects
functional visual ability). Autorefraction. Retinal
photographs to digitally record macula, optic disk,
paracentral and peripheral retina.
▪ Blood pressure assessed using a random zero machine
(seated, after rest for 5 min, cuff size 2/3 upper arm
length: mean of three readings)
▪ Echocardiogram for left ventricular volume, mass and
function, valves, ascending aorta dilatation. Measurement
of myocardial velocities and deformation.
▪ Endothelial dysfunction assessment by peripheral
arterial tonometry (EndoPAT), [41] consisting of digital
recording equipment and two finger thimble-like
probes.
▪ Respiratory Function Tests. Forced expiratory volume
in 1 s (FEV1), Forced Vital Capacity (FVC) and FEV1/
FVC [42]. Static lung volumes [43]. Diffusing capacity
of CO [44]. Single breath nitrogen washout [45].
Maximal exercise testing [46].
▪ Renal function, assessed by a) creatinine clearance
(Ccl) – [Blood test for plasma creatinine in mmol/L. Ccl
calculated from Cockcroft-Gault approximation] and b)
early morning urine for albumin-creatinine ratio [mg/
mmol: <2.2 normal; 2.2–22.6 microalbuminuria; >22.6
proteinuria].
▪ Additional venous blood sample for:
Fasting insulin and glucose – (insulin sensitivity calcu-
lated from QUICKI [47]) lipids; glycated haemoglobin;
cotinine.
Plasma hormones including B-Type Natriuretic Peptide
(BNP), amino terminal proBNP (NT-proBNP), C-Type
Natriuretic Peptide (CNP), amino terminal proCNP (NT-
proCNP), high sensitivity troponin T (hsTNT), renin,
aldosterone.
Stored plasma sample for future use – investigation of
gene-environment interactions; biochemical assays.
Blood volume: 5 × 9 ml EDTA, plus 3 ml A2, plus 2 ×
9 ml lithium heparin for hormones and storage. Plus 4 ml
lithium heparin for biochemistry. Total 70 ml.
Total time for tests including breaks is estimated at
about 2.5–3.5 h (medical/cardiology 1–1.5 h, respiratory
tests 1–1.5 h, visual assessments 0.5 h).
Oral Health investigations will be undertaken by den-
tists from the oral health service of the Canterbury
District Health Board using a standardised protocol
from the 2009 New Zealand Oral Health Survey [48].
The examination will include assessments of the wear-
ing of dentures; history of orthodontic treatment; the
health of oral mucosa; tooth loss, presence of decay,
and dental treatments; plaque, calculus, gingivitis; peri-
odontal tissue destruction; decay experience of coronal
and root surfaces; and the presence of enamel defects.
Total examination time will be approximately 45 min.
Dental examination will be supplemented by question-
naire data on current problems or concerns about oral
health, practise of dental hygiene and use of dental
health services.
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Neuropsychological Functioning will be assessed in
other existing facilities in the University of Otago,
Christchurch, by research staff with appropriate training
and qualifications in psychometric test administration.
The test room will be suitably quiet. The tester will be
blinded to the participants’ background. Testing will
take between 2 to 3 h for each participant, including
breaks as needed, and will include assessments of:
▪ Global cognitive ability/IQ will be assessed using
the Wechsler Abbreviated Scale of Intelligence® –
Second edition (WASI-II), [49] an individually
administered assessment of intelligence for people
aged 6–90 years. This short form consists of four
subtests including Block Design and Matrix
Reasoning (which compose the Perceptual
Reasoning Index) and the Vocabulary and
Similarities subtests (which compose the Verbal
Comprehension Index).
▪ Attention will be measured using the Test of Everyday
Attention (TEA), [50] which assesses selective attention,
sustained attention and switching attention.
▪ Working memory – Visual working memory will be
assessed using a computer administered task adapted from
the Sternberg Spatial Working Memory Paradigm [51].
Auditory working memory will be assessed using the two
elevator counting tasks of the Test of Everyday Attention:
Elevator counting with distraction; Elevator counting with
reversal.
▪ Cognitive flexibility will be assessed by the
Comprehensive Trail Making Test (CTMT), [52]
comprising a standardized set of five visual search and
sequencing tasks, and the Brixton Spatial Anticipation
Test, [53] which is a measure for assessing the ability
to detect and follow a rule.
▪ Visuo-spatial processing and planning will be assessed
using the Benton Judgement of Line Orientation –
Form V [54].
▪ Information processing speed will be assessed using
the Symbol Digit Modalities Test [55].
For participants with a physical or sensorineural dis-
ability some tests may not be possible, and where pos-
sible an alternative form of the test will be used.
Health and social functioning Trained survey inter-
viewers will update information from study Phase 1 on
education, occupational status, health history and self-
assessment of health status, quality of life measures,
current mental health, substance use, family, peer and
partner relationships and other aspects of social func-
tioning. Interviews (2 to 3 h) will be conducted in
private.
Parent/significant other report To gain a further per-
spective on the young person’s health and functioning, a
telephone interview will be conducted with a parent or
significant other person nominated by the respondent.
These interviews will gather a third person perspective
on aspects of the young person’s health and health his-
tory, education and transition to adult roles, the young
person’s behaviour and personality, social and partner
relationships and related issues. Interviews will take
35–45 min and will be conducted by trained survey
interviewers who are independent of the survey team
interviewing the young person, but are not blinded
their background.
Magnetic resonance imaging We will undertake a
cranial MRI scan on all participants who were born
at <28 weeks gestation and a random sample of the
VLBW cohort to bring the total having MRI scans to
150, plus a random 50 controls. Images will be acquired
using a 3-Tesla GE scanner on the Christchurch campus
and analyses undertaken by experienced staff blinded to
the participants’ background. Scanning will take a total of
35–45 min comprising:
▪ Clinical data – T2 and T2 FLAIR images as part of
standard clinical protocol for purposes of a radiologist
read/referral/exclusion and qualitative scoring
▪ T1-weighted images will be used to assess brain
growth and tissue distribution
▪ Diffusion Tensor imaging (DTI) will assess white
matter microstructural development (fractional
anisotropy).
▪ Arterial Spin Labelling (ASL) – a non-invasive
functional measure of cerebral blood flow that
produces quantification of cerebral perfusion and
has good concordance with 15O-PET [56]
▪ Resting State Functional Connectivity (fcMRI) which
provides a method to evaluate regional interactions in
the brain.
Both ASL and fcMRI may be clinically useful as bio-
markers for individuals at increased risk of later cogni-
tive impairment. This protocol, with the addition of
ASL, is the same as that being used at 12 years of age in
a cohort of former <32 week gestation children, who
also had MRI scans at term equivalent, [12] and this
may allow early clues as to longitudinal trajectories of
brain injury and neural plasticity.
Additional studies
Although not part of the primary protocol for the New
Zealand 1986 VLBW Follow-up Study, we will also
undertake two additional studies with separate funding.
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1. DNA methylation and outcomes in VLBW young
adults. We will investigate whether young adults
born with VLBW have differences in DNA
methylation at specific sites in the genome (in
peripheral blood samples), compared with a
matched normal birthweight group, and whether
these traits are associated with growth and
metabolic health outcomes as young adults. Separate
consent is required for this study, which also
requires an additional 10 ml blood sample be taken.
2. C type Natriuretic Peptide (CNP) and vascular
risk in VLBW young adults. CNP is a paracrine
vasoprotective peptide secreted by the vascular
endothelium, and which has anti-inflammatory
actions in rodents and has been shown to be
atheroprotective. Very little CNP normally enters
the circulation but a stable product of the
prohormone (amino terminal proCNP,
NTproCNP) can be readily measured in plasma
and serves as a marker of CNP production in
tissues. Recent studies by the Christchurch group
have defined the normal age and gender related
ranges of plasma NTproCNP concentration in 250
healthy adult subjects without known history of
cardiovascular disorder [57]. We will compare the
plasma NTproCNP concentrations in VLBW
young adults and term born controls and
investigate their relationship with individual
vascular risk factors and with adult height.
Statistical analysis and statistical power
The collected data will enable two types of analyses to be
conducted. Between group comparisons: The principal ana-
lyses will examine between group differences in outcome
(health, neurocognitive assessments, social functioning),
using standard statistical analyses: chi square for differences
in proportions; t-test for independent samples or analysis of
variance for differences in means of continuous outcomes;
Poisson or negative binomial regression for differences in
rates. Where outcome data are non-normally distributed
appropriate data transformations (eg logarithmic) may be
conducted. The VLBW group may be further subdivided to
test for differential effects by severity of disability at age 7
to 8, or by birthweight or gestation. Comparisons may be
further adjusted if necessary for between group differences
in family background characteristics using regression
methods based on the generalised linear model [58]. As-
suming a minimum of 250 recruits from the VLBW cohort
and 100 controls, the study will have 80 % power at alpha
= .05 to detect differences between groups of 30 SD or
greater on continuous outcomes, and ORs in the region of
2.0–3.5 for dichotomous outcomes (depending on the base
rate) [59]. This suggests the study will have adequate power
to detect effect sizes in the small to moderate range. These
differences are well within the anticipated effect sizes based
on existing reports [17, 18]. Subdividing the VLBW group
(for example by level of prior disability) is unlikely to com-
promise study power since the effect sizes are likely to in-
crease for more extreme groups.
Outcome trajectories amongst the VLBW cohort: For
a number of outcomes, for example visual, physical
growth, it will be possible to examine across time con-
tinuities and/or trajectories in outcome from childhood
to adulthood within the VLBW cohort. Depending on
the outcome under consideration, analysis methods may
range from simple tabular methods documenting out-
come in young adulthood conditional on childhood sta-
tus, to simple regression models predicting outcome in
adulthood from measures in childhood, to more com-
plex methods for repeated measures data based on a
generalised estimating equation approach [60] to model
changes in outcome trajectory.
Ethics
The study has received ethics approval from the Upper South
B Regional Ethics Committee (superseded by the Southern
Health and Disability Committee) (ref: URB/12/05/015).
Discussion
The study of adult outcomes after VLBW/VP birth is a
relatively new field and one which is expanding, but
there are important gaps in current knowledge. Many
cohorts date from the 1970’s or early 1980’s when few
infants received antenatal steroids, which reduce both
mortality and morbidity [61]. Some studies are from sin-
gle institutions, [17, 62] or a group of institutions, in-
cluding the Helsinki Study of Very Low Birth Weight
Adults based on 166 VLBW infants born in 1978–85
and which has been highly productive [26, 63]. Of the
few population based studies most are regional [17, 18]
or rely on constrained national registry data [19] (Swed-
ish, [64, 65] Norwegian [66] and Danish [67] studies).
The Netherlands study of VP/VLBW infants born in
1983 [68, 69] is most similar to our NZ cohort but these
infants were not exposed to antenatal corticosteroids. As
more data become available, understanding trends across
studies as well as differences between them will become
important. The New Zealand 1986 VLBW Follow-up
Study investigators are committed to collaborating with
other studies as part of the Adult Born Preterm Inter-
national Collaboration (APIC), which has been initiated
by the Helsinki, Finland group [70].
Additional files
Additional file 1: NZ 1986 VLBW FU Study Cohort Information
Sheet May 2013 Final.
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Additional file 2: NZ 1986 VLBW FU Study Controls Information
Sheet May 2013 Final.
Additional file 3: NZ 1986 VLBW FU Study Information Sheet
Genetics August 2012.
Additional file 4: NZ 1986 VLBW FU Study Consent Form Genetics
Jan 2013.
Additional file 5: NZ 1986 VLBW FU Study Consent Form Genetics
Jan 2013.
Additional file 6: NZ 1986 VLBW FU Study Explanation of
procedures June 2013.
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